Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Etravirine to Doravirine in HIV
NCT05506605Phase 4Unknown
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Percentage of participants with confirmed HIV viral load > 50 copies/mL at 24 weeks. Status: unknown.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05506605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506605.